Johannessen et al., 2001 - Google Patents

The acute effect of valproate on cerebral energy metabolism in mice

Johannessen et al., 2001

Document ID
4591399976491904038
Author
Johannessen C
Petersen D
Fonnum F
Hassel B
Publication year
Publication venue
Epilepsy research

External Links

Snippet

Sodium valproate (VPA) is used in the acute treatment of status epilepticus and mania. We studied the acute effect of VPA on cerebral energy metabolism in awake mice that received VPA 400 mg kg− 1 and [1-13C] glucose or [2-13C] acetate. At 25 min, 13C NMR …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl group being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/06—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins
    • A61K47/16—Organic compounds, e.g. mineral oil, petrolatum, synthetic polyolefins containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Quaternary ammonium compounds, e.g. amides, ureas
    • A61K47/183—Amino acids or aminosulphonic acids, e.g. glycine, EDTA, aspartame

Similar Documents

Publication Publication Date Title
Kircheis et al. Pharmacokinetic and pharmacodynamic properties of L-ornithine L-aspartate (LOLA) in hepatic encephalopathy
Hu et al. Passive and carrier-mediated intestinal absorption components of captopril
Deane et al. “Nutraceuticals” in relation to human skeletal muscle and exercise
Cynober Metabolism of dietary glutamate in adults
Grimble et al. Immunonutrition: role of sulfur amino acids, related amino acids, and polyamines
Johannessen et al. The acute effect of valproate on cerebral energy metabolism in mice
Grimble Adverse gastrointestinal effects of arginine and related amino acids
Aoi et al. Exercise and functional foods
US6579866B2 (en) Composition and method for modulating nutrient partitioning
Clanton et al. Control of seizures by ketogenic diet-induced modulation of metabolic pathways
AU2012244748A1 (en) Nutritional compositions comprising alpha-hydroxyisocaproic acid
Meadows et al. Dietary influence of tyrosine and phenylalanine on the response of B16 melanoma to carbidopa-levodopa methyl ester chemotherapy
HUP0102501A2 (en) Composition comprising a carnitine and glutathione, useful to increase the absorption of glutathione and synergize its effects
James Branched chain amino acids in heptatic encephalopathy
Beaufrere et al. Apparent decreased oxidation and turnover of leucine during infusion of medium-chain triglycerides
Raul et al. Beneficial effects of L-arginine on intestinal epithelial restitution after ischemic damage in rats
Wessner et al. Effect of single and combined supply of glutamine, glycine, N-acetylcysteine, and R, S-α-lipoic acid on glutathione content of myelomonocytic cells
Horiuchi et al. Ornithine ingestion improved sleep disturbances but was not associated with correction of blood tryptophan ratio in Japanese Antarctica expedition members during summer
Hassel et al. Cerebral dicarboxylate transport and metabolism studied with isotopically labelled fumarate, malate and malonate
Humbert et al. Effect of glutamine on glutathione kinetics in vivo in dogs
Oka et al. Arginine‐Enriched Solution Induces a Marked Increase in Muscle Glutamine Concentration and Enhances Muscle Protein Synthesis in Tumor‐Bearing Rats
FR2711529A1 (en) Composition based on amino acids intended for the treatment of an infection or an aggression causing an inflammatory reaction, in animals and in humans.
Van der Meij et al. Effects of acute oral feeding on protein metabolism and muscle protein synthesis in individuals with cancer
Hurley The impact of dietary arginine and citrulline in the neonatal gut
Hanson et al. Transport and metabolism of glutamine and glutamate in the small intestine